Brian retired from his position as Vice President, Technology Development U.K., GlaxoSmithKline Discovery Research in November 2005 and is a co-founder of BB Consultants Ltd, a U.K.-based life sciences consulting company.
Dr. Warrington joined Smith, Kline & French in 1965 and contributed as a medicinal chemist to advances in a large number of therapeutic targets. He was part of the team that identified the first examples of H2-antagonists, and made seminal contributions to the original validation of phosphodiesterases and protein kinases as viable targets for drug intervention, including some of the first demonstrations of the utility of protein kinase inhibitors in the cancer field and the original identification of PDE 5 inhibitors as potential treatments for male erectile dysfunction. Later work in the serotonin field contributed to a long-duration anti-migraine product called frovotriptan.
Dr. Warrington holds a Ph.D. from the University of London, is a Fellow of the Royal Society of Chemistry, a Chartered Scientist and a Chartered Chemist. He is Chairman of the INSIGHT High Throughput Technologies Faraday Partnership, sponsored by the U.K. Government’s Department of Trade and Industry and a member of their Micro Nano Technology Executive Panel. He is also a member of the U.K. Engineering and Physics Science Research Council Nanotechnology Strategy Working Party. He holds an honorary Professorship from the University of Hull, U.K. and currently enjoys a part-time role as a Visiting Scientist in Residence at the University of Cambridge U.K.
Dr. Warrington’s efforts in the field of automation and high throughput technologies have been recognized by the profession in the U.S. and the U.K. In January 2000, he was presented with the Association for Laboratory Automation Achievement Award. In November 2005, Dr. Warrington was awarded the Royal Society of Chemistry’s Millennium Silver Medal for High throughput Drug Discovery Methodologies with the citation, “Distinguished for his pioneering work that led to the creation of the world’s first ‘compound factory’ based on high throughput synthesis, and his leadership in the field of microfluidics for compound synthesis and screening.”